Rutherford Health Plc
Rutherford Health starts treating patients at its new centre in Liverpool
London, UK, 30 July 2020: Rutherford Health plc (the "Company" or "Group" or "Rutherford Health") announces that it has commenced treating patients at the new Rutherford Cancer Centre North West, in Liverpool.
The centre has been approved by the Care Quality Commission to initially offer patients Systemic Anti-Cancer Therapy (SACT) services which includes chemotherapy, immunotherapy, targeted therapies, symptom control as well as blood tests, oncology nurse consultation and supportive therapies. The centre will also offer MRI diagnostic services.
The facility in the Knowledge Quarter in Paddington Village will eventually offer comprehensive cancer services with plans to expand services later this year to include radiotherapy, MR Linac, mammography and ultrasound with high energy proton beam therapy coming online early next year.
The Liverpool centre will be the first in the UK to use an MR Linac machine, which combines an MRI scanner and a linear accelerator, manufactured by Elekta. This delivers targeted radiotherapy that can treat hard to reach tumours. The centre is the fourth in the Rutherford Health network of centres.
Mike Moran, CEO of Rutherford Health, said: "As a son of Liverpool, I am very proud that we are now in a position to start treating cancer patients in the city and the North West. The COVID-19 pandemic has wreaked havoc on cancer care services across the UK and we believe that this centre will be an important development in the fight against cancer.
"The centre is the latest in our state-of-the-art network of Rutherford Cancer Centres. We are delighted with the role that we continue to play in advancing cancer care in the UK especially when it comes to precision radiotherapy. Our goal is to ensure cancer patients throughout the UK can easily access the most advanced treatments without having to travel long distances or even abroad."
Services at the Rutherford Cancer Centre North West will be accessible to private patients under medical insurance, self-pay patients and to NHS patients where NHS contracts are in place.
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
The directors of the Company accept responsibility for the content of this announcement.
Rutherford Health plc
Michael Moran, Chief Executive Officer Tel: +44 (0) 16 3381 0661
Grant Thornton (Corporate Adviser) Tel: +44 (0) 20 7383 5100
Colin Aaronson / Niall McDonald
Media House International 07788 414 856 or 0207 710 0020
Ramsay Smith email@example.com
About Rutherford Health plc
Rutherford Health plc is at the vanguard of advancing cancer care. Developing and building a network of oncology centres across the UK known as the Rutherford Cancer Centres, offering a comprehensive range of cancer treatments to patients.
The first centre in Newport, South Wales, was the first in the UK to offer high energy proton therapy. In addition, each centre also offers radiotherapy, chemotherapy, immunotherapy, diagnostic imaging and supportive care services.
As well as the Rutherford Cancer Centre North West, Rutherford Health plc (formerly known as Proton Partners International Limited) has opened three further centres - the Rutherford Cancer Centre South Wales in Newport, Rutherford Cancer Centre North East in Northumberland and the Rutherford Cancer Centre Thames Valley in Reading, with proton therapy available in those three centres.
Rutherford Health plc has partnered with world-leading healthcare technology providers to equip each centre with the very latest and innovative technology, including IBA, Philips and Elekta.
Rutherford Health plc was founded in 2015 by Mike Moran MBE and UK and international cancer experts, including Professor Edward Karol Sikora, former head of the World Health Organisation's cancer programme.